Search
Calcium citrate
go.drugbank.com/drugs/DB11093ApprovedInvestigationalCalcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements.
Mixtures: Cal-mag (one To One) With Potass & Zinc, Re Ob 90 DHACarbon monoxide
go.drugbank.com/drugs/DB11588ApprovedInvestigationalThe DLCO measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in pulmonary capillaries. The DLCO test is both convenient and simple for the patient to undergo. … to prevent the growth of microorganisms [L2538].
Mixtures: Co-HE-O2-N2 Mixture, Co-NE-O2-N2 MixturePioglitazone
go.drugbank.com/drugs/DB01132ApprovedInvestigational[A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart … uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ).
Mixtures: PIOGLITAZONE E METFORMINA EG, PIOGLITAZONE E METFORMINA EGCategories: Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor ActivityCladribine
go.drugbank.com/drugs/DB00242ApprovedInvestigational[A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718] … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell
Nicotine
go.drugbank.com/drugs/DB00184ApprovedInvestigationalIt is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission.
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Categories: Orexin Receptor AntagonistsErlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalErlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsMitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigational[A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper … [L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix.
Potassium Iodide
go.drugbank.com/drugs/DB06715ApprovedInvestigationalSSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.
Mixtures: TL-Folate, RE NataTagatose
go.drugbank.com/drugs/DB04936InvestigationalIt is commonly found in dairy with a similar texture and sweetened capacity to sucrose but with only a third of the calories. It is approved as a food additive as a low calorie sweetener. … Additionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes.